Genetic Signatures Receives FDA Clearance for EasyScreen™ Gastrointestinal Parasite Detection Kit

05 June 2024 | Wednesday | News

New Highly Automated Molecular Test Identifies 8 Common Parasites in 5 Hours, Set to Revolutionize Gastrointestinal Diagnostics in the US.

Genetic Signatures Limited  a global molecular diagnostics company announces that the US Food & Drug Administration ("FDA") has cleared the Company's EasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 automated workflow[1] for marketing and sale in the US.

Genetic Signatures' EasyScreen™ Gastrointestinal Parasite Detection Kit has the broadest coverage of the FDA cleared molecular tests and is able to identify 8 of the most common and clinically relevant gastrointestinal parasites in a single test, representing approximately 90%[2] of all gastrointestinal Parasitic infections in the US. Genetic Signatures' EasyScreen™ Gastrointestinal Parasite Detection Kit is highly automated and is able to provide a result for all 8 targets in approximately 5 hours.

The current practice for gastrointestinal parasite testing is predominantly microscopic examination using O&P[3] testing, that is time-consuming, labour intensive, slow to provide a result, of variable sensitivity and frequently has poor patient compliance across multi sample protocols. It is estimated there are approximately 65 million annual cases of parasitic gastrointestinal infections in the US which result in approximately 5.5 million O&P tests each year.

Genetic Signatures is well-prepared for the commercial launch of its EasyScreen™ Gastrointestinal Parasite Detection Kit. The Company has installed instruments and completed training at nine customer‑experience sites which span a range of customer groups including hospitals, health departments and corporate pathology providers under a customer-experience program. The Company has received positive feedback from these sites and expects some will become the initial commercial customers. Furthermore, the CPT codes which are relevant for providing reimbursement to end users from both public and private payors have been identified. Genetic Signatures expects first commercial sale of the kit in the US within 60 – 90 days of this clearance once appropriately packaged and labelled product is available and the Company's pathology provider customers have completed their internal technology evaluation and approval process.

"We are very excited to have secured our first FDA clearance for a unique and highly differentiated molecular test based on our proprietary 3base® technology" said Neil Gunn, Interim CEO"This has been a key focus for the Company as the US is the largest single market for molecular diagnostics representing approximately 40% of the global market. We believe the unique configuration of our test combined with the significant operational efficiencies and potential impact on patient management will make this an attractive product for laboratories and pathology providers in the US."


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in